Integrated DNA Technologi?es Enhances its qPCR Probe Portfolio
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has further expanded its portfolio of PrimeTime® qPCR products with the launch of two new probes. The PrimeTime Eco Probe and PrimeTime Mini LNA Probe complete the existing offering, providing new options for customers performing gene expression and genotyping experiments.
Developed to support customers looking for a cost-effective option at the mid-scale range, the Eco Probe is delivered at a normalised yield of 2.5 nmoles, sufficient for approximately 500 reactions, bridging the space between the existing PrimeTime Mini qPCR Probe (0.5 nmole normalized yield, 100 reactions) and the 100 nmole synthesis scale (minimum guaranteed yield of 10 nmoles). If ordered with the option of an internal ZEN quencher, the double-quenched PrimeTime Eco Probe will generate less background noise, while increasing end point signal, to significantly boost qPCR sensitivity and precision when compared to traditional single-quenched probes. The Eco Probe is available with a FAM/ZEN/IA Black FQ dye/quencher combination.
When genotyping via PCR, it is often useful to be able to perform a few reactions using a small subset of probes, in order to test and consequently optimise LNA probe design. The new PrimeTime Mini LNA Probes enable customers to do as few as 100 reactions, allowing preliminary experiments to be performed at a low initial cost.
Guidelines for LNA probe design are available online, under the Overview tab to aid users in their initial design. IDT can also provide full design support, if required — design fees may apply. The Mini LNA Probes join the existing 250 nmole PrimeTime LNA Probes, which provide 8000 reactions and are ideal for large-scale screening.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...